U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362264) titled 'A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors' on Jan. 07.
Brief Summary: To evaluate the safety and tolerability of the combination therapy of SH006 injection in patients with advanced solid tumors
Study Start Date: July 01, 2025
Study Type: INTERVENTIONAL
Condition:
Liver Cancer
Intervention:
DRUG: SH006
The dosage of SH006 is 15 mg/kg Q3W or 30 mg/kg Q3W, with a treatment cycle of 21 days
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
Disclaimer: Curated by HT Syndication....